Ozempic and Insulin Resistance: Clinical Evidence

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide), a GLP-1 receptor agonist, does show clinical evidence for improving insulin sensitivity in people with type 2 diabetes. However, individual response varies significantly based on metabolic factors, baseline insulin levels, and genetic predispositions in GLP-1 signaling pathways.

Insulin resistance is a foundational metabolic dysfunction affecting millions. Understanding whether a GLP-1-based approach is right for you requires more than brand recognition—it requires assessment of your metabolic markers, genetic context, and informed provider guidance. PlexusDx specializes in precision-wellness approaches that connect these factors.

How GLP-1 Receptor Agonists Address Insulin Resistance

GLP-1 receptor agonists work by enhancing the body's natural insulin secretion in response to meals, slowing gastric emptying, and reducing hepatic glucose production. These mechanisms collectively improve insulin sensitivity over time. Clinical studies document improvements in HOMA-IR (Homeostasis Model Assessment for Insulin Resistance) scores in GLP-1-treated patients.

The insulin-sensitizing effect is distinct from weight loss alone. Even patients with modest weight reduction show improved fasting insulin levels and decreased insulin resistance markers. This suggests a direct metabolic action beyond caloric deficit, making GLP-1 agonists relevant for metabolic dysfunction management regardless of obesity status.

Metabolic Biomarkers That Inform Treatment Response

Before starting any GLP-1-based therapy, baseline assessment of fasting insulin, HOMA-IR, HbA1c, and lipid profiles provides critical context. These biomarkers predict baseline insulin resistance severity and can help estimate the magnitude of response you might expect. Individual variation in baseline insulin dynamics significantly influences treatment outcomes.

Repeat biomarker assessment at 3-6 months during treatment helps confirm metabolic improvement and guides dose optimization. Providers use these markers to differentiate between weight-loss-driven improvement and direct insulin sensitivity enhancement, informing long-term treatment strategy.

Biomarker	What It Measures	Relevance to GLP-1 Response
Fasting Insulin	Baseline pancreatic insulin output at rest	High baseline fasting insulin may predict stronger GLP-1 response; improvement indicates restored insulin sensitivity
HOMA-IR Score	Quantified insulin resistance calculation	Gold standard for tracking insulin resistance; direct measure of GLP-1 efficacy beyond weight loss
HbA1c	3-month average blood glucose	Tracks glycemic control; GLP-1 effects on HbA1c reflect both insulin sensitivity and appetite modulation
Fasting Glucose	Blood sugar without food stimulus	Elevated fasting glucose indicates hepatic insulin resistance; GLP-1 reduces hepatic glucose output

Genetic Predispositions in GLP-1 Signaling Pathways

Individual variation in GLP-1 receptor function is partly determined by genetic factors. Variants in the GLP1R gene (such as rs6923761) and related metabolic pathways (GIPR rs1800437, MC4R rs17782313, FTO rs9939609) influence how your cells respond to GLP-1 agonists. These predispositions do not predict exact medication response, but may help provide context for expected metabolic adaptations.

Testing these genetic pathways can support a more nuanced conversation with your provider about whether a GLP-1-based approach aligns with your biological predisposition toward insulin sensitivity improvement. This information should always be interpreted alongside clinical biomarkers and your individual health history.

Who Benefits Most: Clinical Criteria and Provider Guidance

Ozempic is FDA-approved for type 2 diabetes management and shows clinical benefit for people with baseline insulin resistance, elevated fasting insulin, or HOMA-IR scores above 2.5. Benefits are most evident in people with metabolic dysfunction who also have cardiovascular risk factors or modest obesity. However, individual response varies, and provider assessment is essential.

Not all insulin resistance presentations respond equally. People with primary beta-cell dysfunction, advanced kidney disease, or history of medullary thyroid cancer require careful evaluation. Your provider should assess your full metabolic profile, medication interactions, and personal health goals before recommending GLP-1 therapy. Genetic and biomarker context can enhance that conversation, but clinical judgment remains paramount.

How PlexusDx Supports a More Personalized Approach

PlexusDx offers compounded semaglutide and tirzepatide formulations at transparent, flat monthly pricing—no dose-based escalation fees. Your dose may need to go up. Your price won't. Access to these medications alongside biomarker tracking and genetic pathway assessment enables a more integrated approach to insulin resistance management than brand-only options.

The Precision Peptide Genetic Test evaluates predispositions in GLP-1 receptor signaling (GLP1R rs6923761), glucose-dependent insulinotropic polypeptide signaling (GIPR rs1800437), and melanocortin-4 receptor pathways (MC4R rs17782313) that influence metabolic response. These results may help provide context for how your body may respond to GLP-1-based therapy, though genetic predisposition does not guarantee specific outcomes and should be interpreted with your healthcare provider.

Understanding your metabolic biomarker baseline and genetic pathway predispositions creates a foundation for informed decision-making with your provider. PlexusDx supports this precision-wellness model by connecting affordable compounded medication access with actionable genetic and biomarker insights, enabling a treatment approach tailored to your individual metabolic profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.